Market Skepticism Weighs on Novo Nordisk Despite Cardiovascular Breakthrough

Shares of Danish pharmaceutical giant Novo Nordisk experienced continued pressure on Friday, puzzling observers who expected a positive market response to groundbreaking trial data for its blockbuster drug Wegovy. The decline occurred despite compelling new evidence demonstrating Wegovy’s significant cardiovascular advantages over competing treatments.

Presented at the European Congress of Cardiology, results from the STEER study revealed Wegovy reduces the risk of major cardiovascular events?including heart attack and stroke?by an impressive 57% when compared to tirzepatid, a competing drug from Eli Lilly. This substantial margin could provide Novo Nordisk with a critical competitive edge in the highly contested weight-loss medication market.

This development represents a strategic victory for Novo Nordisk. While Eli Lilly’s products have demonstrated effectiveness Read more...